Navigation Links
Mindray Medical Completes Acquisition of Datascope's Patient Monitoring Business

SHENZHEN, China, May 15 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading China-based developer, manufacturer and marketer of medical devices worldwide, today announced the completion of its acquisition of Datascope Corporation's patient monitoring device business pursuant to the terms of the definitive agreement entered into on March 11, 2008.

The combined business benefits from Mindray's integrated engineering and manufacturing platforms, Datascope's established brands, reputable products and services and extensive direct sales and service capabilities in the United States and Western Europe.

''We are pleased to complete this acquisition, which represents a significant milestone on our path to becoming a leading global medical device company,'' said Xu Hang, Mindray's chairman and co-chief executive officer. ''This transaction ensures sustainable high growth for our international business and gives us immediate access to an established network of hospital customers in the U.S., the world's single largest healthcare market. We're optimistic about the growth potential of our combined business and believe we are now even better positioned to address the growing trend of cost-conscious healthcare spending worldwide.''

Under the agreement, Mindray has acquired Datascope's patient monitoring device business for a total purchase price of US$209 million in cash, as adjusted for working capital at the closing date. Mindray expects to achieve over US$30 million in run-rate synergies from the acquisition in the areas of manufacturing, SG&A and R&D in 2011.

About Mindray

Mindray Medical International Limited is a leading developer, manufacturer and marketer of medical devices worldwide. Established in 1991, Mindray offers a broad range of products across three primary business segments: patient monitoring & life support products, in-vitro diagnostic products, and medical imaging systems. Mindray is globally headquartered in Shenzhen, China, with U.S. headquarters in Mahwah, New Jersey. Mindray also has sales and service offices internationally in Amsterdam, Istanbul, London, Mexico City, Moscow, Mumbai, Sao Paulo, Seattle, Toronto and Vancouver. For more information, please visit .

Cautionary Note Regarding Forward Looking Statements

This press release contains "forward-looking statements" including those related to the anticipated run-rate synergies that Mindray expects to achieve including timing of achieving such synergies and their amount. These statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. It is possible that our actual synergies achieved may differ, possibly materially, from the anticipated synergies indicated in these forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including but not limited to: the expected growth of the medical device market in China and internationally; relevant government policies and regulations relating to the medical device industry; market acceptance of our products; our expectations regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 5 of our annual report on Form 20-F, filed on June 26, 2007. Our results of operations for the first quarter of 2008 and for fiscal year 2008 are not necessarily indicative of our operating results for any future periods. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release.

For investor inquiries please contact:

In China:

Susan Du

Mindray Medical International Limited

Tel: +86-755-2658-2518


Justin Knapp

Ogilvy Public Relations Worldwide, Beijing

Tel: +86-10-8520-6556


In the United States:

Jeremy Bridgman

Ogilvy Public Relations Worldwide, New York

Tel: +1-212-880-5363

SOURCE Mindray Medical International Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
2. Mindray to Report Third Quarter 2007 Financial Results on November 1, 2007
3. Mindray to Attend 2007 RSNA Conference in Chicago
4. Mindray to Attend 2008 CLSA Asia Investors Forum
5. Mindray to Exhibit at 2008 European Congress of Radiology Annual Meeting
6. Mindray to Report Fourth Quarter and Fiscal Year 2007 Financial Results on March 5, 2008
7. Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results
8. Mindray to Attend the 11th Credit Suisse Asian Investment Conference
9. Mindrays Laptop-size M5 and BS-200 Receive FDA Clearance
10. Mindray to Attend the JPMorgan 4th Annual China Conference
11. Mindray to Exhibit at 2008 China International Medical Equipment Fair
Post Your Comments:
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: